hat
"Nou ap kenbe tout natirèl,"te di Jennifer Puck, yon ekspè SCID nan Inivèsite Kalifòni, San Francisco, ki exploration potentiel de Crispr pou trete move maladi. Difficiles, nan yon pwosè a byen bonè pou trete SCID itilize jèn terapi, a relèv jèn intégrée nan yon kote a gen chans e te koz ke leucémie nan senk de la 20 pasyan pwan swen. Pwoblèm sa Bondye te pare, men teknik la ka toujou difisil jwenn dwa.
eng
“You are keeping everything natural,” says Jennifer Puck, a SCID expert at the University of California, San Francisco, who is exploring the potential of Crispr to treat the disease. Notoriously, in an early trial to treat SCID using gene therapy, the replacement gene incorporated in an unfortunate location and caused leukaemia in five of the 20 patients treated. That problem has been fixed, but the technique can still be tricky to get right.